Treats erectile dysfunction. ANDA 208324, held by Alembic. Vardenafil Hydrochloride.
As of Nov 16, 2026, ANDA 208324 (Vardenafil Hydrochloride), held by Alembic, was first approved by FDA on Nov 16, 2018, with 0 approved supplements and 0 published complete response letters.
Vardenafil hydrochloride orally disintegrating tablets are indicated for the treatment of erectile dysfunction.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 16, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Vardenafil Hydrochloride10MG · tablet, orally disintegrating;oral | Vardenafil Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters